Opendata, web and dolomites

MBLIs SIGNED

New Approaches to Metallo-β-Lactamase Inhibitors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MBLIs project word cloud

Explore the words cloud of the MBLIs project. It provides you a very rough idea of what is the project "MBLIs" about.

rendering    variations    health    human    pathogens    spends    pbps    acids    ms    selectivity    phosphonates    public    clinically    relevance    ring    alarming    sites    therapies    active    pioneer    enzymes    declining    combination    serine    60    clinical    dcls    mechanism    breadth    die    31p    penicillin    mbli    bacterial    society    desired    molecules    mechanisms    biological    hydrolysis    structures    billion    denaturing    almost    mechanistically    healthcare    patients    antibiotic    occurrence    antibiotics    inspire    mbl    contain    gt    beta    protein    unrelated    small    reporter    directed    lactam    metallo    efficacy    inactive    inhibition    chemistry    threat    biology    spectrum    resistance    lactamases    screening    resistant    obtain    little    inhibited    sbl    equilibrated    least    compounds    phosphinic    structurally    representative    utility    coupled    nmr    interdisciplinary    structural    caused    binding    situation    critical    broad    medicinal    25    synthesis    mbls    inhibitors    infections    clear    mblis    unlike    generation    representing    dcc    blas    organic    serious    bla    esi    panel    modified    global    catalyse   

Project "MBLIs" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD 

Organization address
address: WELLINGTON SQUARE UNIVERSITY OFFICES
city: OXFORD
postcode: OX1 2JD
website: www.ox.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://schofield.chem.ox.ac.uk/mariosmarkoulides.aspx
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) coordinator 183˙454.00

Map

 Project objective

The increasing problem of antibiotic resistance is a major global public health concern. In the EU 25,000 patients die each year due to infections caused by multi-resistant bacterial pathogens, and the EU spends at least 1.5 billion euro per year on healthcare costs. The β-lactam antibiotics are the most important antibiotics representing >60% of small molecules in clinical use. BLAs contain a β-lactam ring which is critical for penicillin-binding protein inhibition. However, BLA efficacy is declining due to resistance mechanisms including the widespread occurrence of β-lactamases, which catalyse β-lactam hydrolysis. Metallo-β-lactamases, long-considered as of little clinical relevance, now present a serious global threat to almost all BLAs, rendering the development of approaches to MBL inhibitors important. Unlike the serine β-lactamases, the MBLs are structurally and mechanistically unrelated to PBPs, and are not inhibited by current mechanism-based SBL inhibitors. Due to variations in MBL structures, a major challenge in MBL inhibition is the development of compounds with the breadth of selectivity necessary for clinical utility. Society is now in an alarming situation and there is a clear need for the development of an MBLI:β-lactam-based combination therapies. The aim of my proposed work is to pioneer, enable and inspire the generation of broad-spectrum MBLIs active against a panel of clinically representative MBLs, but inactive against human enzymes with related active sites. To obtain the desired objective, novel approaches are proposed and include the use of phosphonates and phosphinic acids for: (a) MBL-directed DCC coupled to analysis by non-denaturing ESI-MS and 31P-NMR, (b) 31P-NMR reporter screening method, (c) pre-equilibrated DCLs for MBL-directed DCC, and (d) the synthesis of modified inhibitors. The study will be interdisciplinary and encompass organic synthesis, biological MS/NMR, structural biology, and medicinal chemistry.

 Publications

year authors and title journal last update
List of publications.
2016 David Yuxin Wang, Martine I Abboud, Marios S Markoulides, Jürgen Brem, Christopher J Schofield
The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam
published pages: 1063-1084, ISSN: 1756-8919, DOI: 10.4155/fmc-2016-0078
Future Medicinal Chemistry 8/10 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MBLIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MBLIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

BB-SLM (2020)

Polychromatic digital optics for structured light

Read More  

NSTree (2020)

Understanding substrate delivery for cell wall biosynthesis in plants

Read More  

ReproMech (2019)

The Molecular Mechanisms of Cell Fate Reprogramming in Vertebrate Eggs

Read More